Get the Stockscreener App
3.76
1.35%
0.05
After Hours:
3.69
-0.07
-1.86%
Evaxion A S Adr stock is traded at $3.76, with a volume of 161.44K.
It is up +1.35% in the last 24 hours and up +14.63% over the past month.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
See More
Previous Close:
$3.71
Open:
$3.96
24h Volume:
161.44K
Relative Volume:
0.82
Market Cap:
$33.92M
Revenue:
$7.50M
Net Income/Loss:
$-9.85M
P/E Ratio:
-2.7197
EPS:
-1.3825
Net Cash Flow:
$-6.62M
1W Performance:
+32.86%
1M Performance:
+14.63%
6M Performance:
-11.53%
1Y Performance:
-32.98%
1-Day Range:
$3.65
$4.00
1-Week Range:
$2.972
$4.50
52-Week Range:
$2.72
$6.92
Evaxion A S Adr Stock (EVAX) Company Profile
Compare EVAX vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
3.76 | 33.92M | 7.50M | -9.85M | -6.62M | -1.3825 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Maxim Group | Buy |
| Apr-02-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Feb-12-24 | Initiated | H.C. Wainwright | Buy |
Evaxion A S Adr Stock (EVAX) Latest News
EVAX Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Reports No RevenueEstimate Dispersion - www.dars.gov.et
POM Stock Price, Quote & News - Syfe
Evaxion (EVAX) ADR Ticks Up to $3.08 as Micro-Cap Biotech Holds RangeInstitutional Sentiment - https://www.siam.in/
Evaxion (EVAX) ADR Ticks Up to $3.08 as Micro-Cap Biotech Holds RangeLeveraged ETF Flow - dars.gov.et
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting - GlobeNewswire Inc.
Evaxion A/S (EVAX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Evaxion A/SAmerican Depositary Share (NQ: EVAX - The Chronicle-Journal
Evaxion Biotech Boosts Share Capital With August 2026 ATM ADS Offering - The Globe and Mail
Evaxion Biotech Boosts Share Capital With August 2026 ATM ADS Offering - The Globe and Mail
Evaxion (EVAX) taps investors with new ADS sale - Stock Titan
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Raises Questions on Cash BurnEarnings Sentiment Score - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentRevenue Beat Analysis - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentOperating Margin Analysis - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentGAAP Earnings Report - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentNew Analyst Coverage - dars.gov.et
EVAX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentMid-Term Outlook - dars.gov.et
Evaxion (EVAX) Levels: Posts a 0.91% Gain to $3.31 in Latest Trading; Boundary Watch: Traders Can Monitor the $3.14-$3.48 Range in the Current UpdateMcClellan Summation - dars.gov.et
Evaxion (EVAX) Levels: Posts a 0.91% Gain to $3.31 in Latest Trading; Boundary Watch: Traders Can Monitor the $3.14-$3.48 Range in the Current UpdateRisk Parity Rebalance - www.dars.gov.et
Evaxion (EVAX) Levels: Posts a 0.91% Gain to $3.31 in Latest Trading; Boundary Watch: Traders Can Monitor the $3.14-$3.48 Range in the Current UpdateGamma Flip Level - dars.gov.et
Evaxion Biotech Earnings Call: Data Strength, Cash Strain - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
EVAX Q1 2026 Earnings: Wider-than-Expected Loss of -$0.50 Per Share as Pre-Revenue Biotech Advances PipelineLow Estimate Range - careplusvn.com
Evaxion (EVAX) Steadies at $2.97 as Biotech ADS Tests Key $3.12 ResistanceInside Day Breakout - careplusvn.com
Evaxion (EVAX) Steadies at $2.97 as Biotech ADS Tests Key $3.12 ResistanceLiquidity Sweep - dars.gov.et
Evaxion (EVAX) Steadies at $2.97 as Biotech ADS Tests Key $3.12 ResistanceWatchlist Stock Ideas - dars.gov.et
Evaxion (EVAX) Holds Near $2.82 as Consolidation Range PersistsChaikin Flow - careplusvn.com
Evaxion (EVAX) Holds Near $2.82 as Consolidation Range PersistsDip Buy Trade - dars.gov.et
Evaxion (EVAX) Holds Near $2.82 as Consolidation Range PersistsDiagonal Spread Trade - dars.gov.et
Evaxion (EVAX) Edges Higher as Support Holds, Resistance LoomsTrading Ideas - dars.gov.et
Evaxion Biotech A/S Adr (EVAX) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 - GlobeNewswire Inc.
Evaxion (EVAX) Dips 1.25% as Stock Tests Support Near $3.01TICK Divergence - dars.gov.et
European ADRs Rose As Biopharma Names Led The Pack - Finimize
US-Traded European Stocks Slipped As Arm And ArcelorMittal Fell - Finimize
Evaxion A/S Sponsored ADR Actuals & Estimates (NASDAQ:EVAX) - TradingView
Evaxion receives Prix Galien UK Award for Best digital health solution - Finansavisen
European ADRs Edged Higher As Biotech Led Friday’s Moves - Finimize
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia - Finansavisen
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia - GlobeNewswire Inc.
European ADRs Started The Week In The Green - Finimize
European ADRs Edged Higher In US Trading - Finimize
EVAXEvaxion A/S ADR Options - Finviz
EVAX - Finviz
Evaxion Biotech Signals Strong R&D Momentum Amid Cash Constraints - TipRanks
Most VolatileStock ScreenerNews - Finviz
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer - GlobeNewswire Inc.
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer - Finansavisen
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma - GlobeNewswire Inc.
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial - Finansavisen
Evaxion concludes Annual General Meeting - Finansavisen
Evaxion A S Adr Stock (EVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.09%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):